-

10:42:40 AM

SYRS Stock News

SYRS - Syros Pharmaceuticals Inc.

06/08/23 7:30 AM

Nasdaq : SYRS

conferenceslow float

Syros to Present at Sidoti June 2023 Virtual Small-Cap Conference

Syros Pharmaceuticals, a biopharmaceutical company committed to advancing new standards of care for the frontline treatment of hematologic malignancies, today announced that its Chief Executive Officer, Nancy Simonian, M.D., will present a corporate overview at the Sidoti June 2023 Virtual Small-Cap Conference. Management will also be available for...

RHEA-AI

neutral

06/01/23 4:30 PM

Nasdaq : SYRS

low float

Syros Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Syros Pharmaceuticals, a biopharmaceutical company committed to advancing new standards of care for the frontline treatment of hematologic malignancies, today announced the grant of restricted stock unit awards for an aggregate of 29,250 shares of Syros common stock to three newly hired employees in connection with commencing employment with Syros.

RHEA-AI

very positive

05/25/23 5:05 PM

Nasdaq : SYRS

clinical triallow float

Syros Presents Data from Phase 1/1b Clinical Trial of SY-5609 in Advanced Solid Tumors at ASCO Annual Meeting

Syros Pharmaceuticals, a biopharmaceutical company committed to advancing new standards of care for the frontline treatment of hematologic malignancies, today announced new clinical data from the Phase 1/ 1 b clinical trial evaluating SY-5609, its highly selective and potent inhibitor of CDK7, in patients with relapsed/refractory pancreatic ductal...

RHEA-AI

positive

05/10/23 7:30 AM

Nasdaq : SYRS

earningslow float

Syros Reports First Quarter 2023 Financial Results and Provides a Corporate Update

Syros Pharmaceuticals, a biopharmaceutical company committed to advancing new standards of care for the frontline treatment of hematologic malignancies, today reported financial results for the quarter ended March 31, 2023 and provided a corporate update. “In 2023, we are focusing on clinical execution, with the goal of delivering tamibarotene and...

RHEA-AI

neutral

05/09/23 7:00 AM

Nasdaq : SYRS

conferenceslow float

Syros to Present at JMP Securities 2023 Life Sciences Conference

Syros Pharmaceuticals, a biopharmaceutical company committed to advancing new standards of care for the frontline treatment of hematologic malignancies, today announced that its Chief Executive Officer, Nancy Simonian, M.D., will participate in a fireside chat at the JMP Securities 2023 Life Sciences Conference. Management will also be available for...

RHEA-AI

neutral

05/03/23 7:30 AM

Nasdaq : SYRS

conferencesearningslow float

Syros to Report First Quarter 2023 Financial Results on Wednesday, May 10, 2023

Syros Pharmaceuticals, a biopharmaceutical company committed to advancing new standards of care for the frontline treatment of hematologic malignancies, today announced that it will host a live conference call and webcast at 8:30 a.m. ET on Wednesday, May 10, 2023 to report its first quarter 2023 financial results and provide a corporate update.

RHEA-AI

neutral

05/02/23 7:00 AM

Nasdaq : SYRS

low float

Syros Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Syros Pharmaceuticals, a biopharmaceutical company committed to advancing new standards of care for the frontline treatment of hematologic malignancies, today announced the grant of restricted stock unit awards for an aggregate of 17,800 shares of Syros common stock to two newly hired employees in connection with commencing employment with Syros.

RHEA-AI

very positive

03/02/23 7:30 AM

Nasdaq : SYRS

earningslow float

Syros Reports Fourth Quarter and Full Year 2022 Financial Results and Provides a Corporate Update

Syros Pharmaceuticals, a biopharmaceutical company committed to advancing new standards of care for the frontline treatment of hematologic malignancies, today reported financial results for the quarter and full-year ended December 31, 2022 and provided a corporate update. “In 2022, we advanced our efforts to develop new standards of care for the...

RHEA-AI

positive

02/28/23 7:30 AM

Nasdaq : SYRS

conferenceslow float

Syros to Participate in Upcoming Investor Conferences in March

Syros Pharmaceuticals, a biopharmaceutical company committed to advancing new standards of care for the frontline treatment of hematologic malignancies, today announced that its Chief Executive Officer, Nancy Simonian, M.D., will participate in a panel discussion and present a corporate overview at two upcoming investor conferences in March.

RHEA-AI

neutral

02/23/23 7:30 AM

Nasdaq : SYRS

conferencesearningslow float

Syros to Report Fourth Quarter and Full Year 2022 Financial Results on Thursday, March 2, 2023

Syros Pharmaceuticals, a biopharmaceutical company committed to advancing new standards of care for the frontline treatment of hematologic malignancies, today announced that it will host a live conference call and webcast at 8:30 a.m. ET on Thursday, March 2, 2023 to report its fourth quarter and full year 2022 financial results and provide a corporate...

RHEA-AI

neutral

1 2 3 4 5 6 7 8 9 Next

SYRS Data

IndustryPharmaceutical Preparation Manufacturing
Websitesyros.com
CeoNancy Simonian
Security nameSyros Pharmaceuticals Inc.
Issue typecs
SectorManufacturing
Sic code2834
Employees118
Tags
- Health Technology
- Biotechnology
- Manufacturing
- Pharmaceutical Preparation Manufacturing
Address35 Cambridge Park Drive
StateMassachusetts
CityCambridge
Zip02140
CountryUS
Phone16177441340

About Syros Pharmaceuticals Inc.

Syros is redefining the power of small molecules to control the expression of genes. Based on its unique ability to elucidate regulatory regions of the genome, Syros aims to develop medicines that provide a profound benefit for patients with diseases that have eluded other genomics-based approaches. Syros is advancing a robust clinical-stage pipeline, including: SY-1425, a first-in-class oral selective RARα agonist in RARA-positive patients with higher-risk myelodysplastic syndrome and acute myeloid leukemia; SY-2101, a novel oral form of arsenic trioxide in patients with acute promyelocytic leukemia; and SY-5609, a highly selective and potent oral CDK7 inhibitor in patients with select solid tumors. Syros also has multiple preclinical and discovery programs in oncology and monogenic diseases.